Mutation profile of study population and correlation with clinical response. A, Frequency of mutations (as % of patients) in patients at trial entry. Patients are further divided according to best response achieved. B, Frequency of number of mutations detected per patient pretreatment. C, Comparison of mutations detected in RAvVA cohort compared with recently published AML cohorts [Papa: Papaemmanuil et al. (19); TCGA(20): Welch et al. (21)]. D, Correlation of combinations of detected mutations with CR and OS: only genes where there were at least five patients with two mutations are included in this analysis. Unadjusted P values from a Fisher exact test are shown. The top right half of the table (values in shades of green) show mutation combinations significantly associated with decreased OS. The bottom left half of the table (with values in shades of yellow) shows absence of significant mutation combinations predictive of CR. Key: CR (includes CR, CRi), PR, NR (no response including stable disease and progressive disease), ID (induction death), NA (response data not available).